Rocket Pharmaceuticals, Inc. Fair Value of Assets Acquired
Rocket Pharmaceuticals, Inc. (RCKT) reported Fair Value of Assets Acquired of $1.67 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-07.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:FairValueOfAssetsAcquired · last filed 2023-11-07
- Rocket Pharmaceuticals, Inc. fair value of assets acquired for the quarter ending 2023-09-30 was $405.00K, a 69.82% decline year-over-year.
- Rocket Pharmaceuticals, Inc. fair value of assets acquired for the quarter ending 2023-06-30 was -$529.00K.
- Rocket Pharmaceuticals, Inc. fair value of assets acquired for the quarter ending 2023-03-31 was $1.79M, a 9.72% increase year-over-year.
- Rocket Pharmaceuticals, Inc. fair value of assets acquired for the quarter ending 2022-12-31 was $348.00K.
- Rocket Pharmaceuticals, Inc. fair value of assets acquired for fiscal 2022 was $2.10M, a 187.77% increase from fiscal 2021.
- Rocket Pharmaceuticals, Inc. fair value of assets acquired for fiscal 2021 was $728.00K, a 58.54% decline from fiscal 2020.
- Rocket Pharmaceuticals, Inc. fair value of assets acquired for fiscal 2020 was $1.76M, a 62.24% decline from fiscal 2019.
- Rocket Pharmaceuticals, Inc. fair value of assets acquired for fiscal 2019 was $4.65M.
| Period end | Fair Value of Assets Acquired 3 month | Fair Value of Assets Acquired 3 month as first filed | Fair Value of Assets Acquired 6 month | Fair Value of Assets Acquired 6 month as first filed | Fair Value of Assets Acquired 9 month | Fair Value of Assets Acquired 9 month as first filed | Fair Value of Assets Acquired 12 month | Fair Value of Assets Acquired 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2023-09-30 | $405.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$124.00K derived: sum of 2 quarters · filed 2023-11-07 | $1.67M 10-Q · filed 2023-11-07 | $2.02M derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2023-06-30 | -$529.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $1.26M 10-Q · filed 2023-08-09 | $1.61M derived: sum of 3 quarters · filed 2023-08-09 | $2.96M derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2023-03-31 | $1.79M 10-Q · filed 2023-05-05 | $2.14M derived: sum of 2 quarters · filed 2023-05-05 | $3.48M derived: sum of 3 quarters · filed 2023-11-07 | $2.25M derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2022-12-31 | $348.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $1.69M derived: sum of 2 quarters · filed 2023-11-07 | $460.00K derived: sum of 3 quarters · filed 2023-11-07 | $2.10M 10-K · filed 2023-02-28 | ||||
| 2022-09-30 | $1.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $112.00K derived: sum of 2 quarters · filed 2023-11-07 | $1.75M 10-Q · filed 2023-11-07 | $1.34M derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2022-06-30 | -$1.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $405.00K 10-Q · filed 2023-08-09 | $1.00K derived: sum of 3 quarters · filed 2023-08-09 | -$261.00K derived: sum of 4 quarters · filed 2023-08-09 | ||||
| 2022-03-31 | $1.64M 10-Q · filed 2023-05-05 | $1.23M derived: sum of 2 quarters · filed 2023-05-05 | $969.00K derived: sum of 3 quarters · filed 2023-05-05 | $1.72M derived: sum of 4 quarters · filed 2023-05-05 | ||||
| 2021-12-31 | -$404.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$666.00K derived: sum of 2 quarters · filed 2023-02-28 | $80.00K derived: sum of 3 quarters · filed 2023-02-28 | $728.00K 10-K · filed 2023-02-28 | ||||
| 2021-09-30 | -$262.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $484.00K derived: sum of 2 quarters · filed 2022-11-04 | $1.13M 10-Q · filed 2022-11-04 | $1.11M 10-Q · filed 2021-11-05 | -$2.74M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2021-06-30 | $746.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.39M 10-Q · filed 2022-08-09 | $1.27M 10-Q · filed 2021-08-09 | -$2.48M derived: sum of 3 quarters · filed 2023-02-28 | -$808.00K derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2021-03-31 | $648.00K 10-Q · filed 2022-05-06 | $337.00K 10-Q · filed 2021-05-10 | -$3.22M derived: sum of 2 quarters · filed 2023-02-28 | -$1.55M derived: sum of 3 quarters · filed 2023-02-28 | -$392.00K derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2020-12-31 | -$3.87M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$2.20M derived: sum of 2 quarters · filed 2023-02-28 | -$1.04M derived: sum of 3 quarters · filed 2023-02-28 | $1.76M 10-K · filed 2023-02-28 | $1.46M 10-K · filed 2021-03-01 | |||
| 2020-09-30 | $1.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $2.83M derived: sum of 2 quarters · filed 2021-11-05 | $5.63M 10-Q · filed 2021-11-05 | $6.74M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-06-30 | $1.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $3.96M 10-Q · filed 2021-08-09 | $5.07M derived: sum of 3 quarters · filed 2022-02-28 | $7.89M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-03-31 | $2.80M 10-Q · filed 2021-05-10 | $3.91M derived: sum of 2 quarters · filed 2022-02-28 | $6.73M derived: sum of 3 quarters · filed 2022-02-28 | $3.05M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2019-12-31 | $1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $3.93M derived: sum of 2 quarters · filed 2022-02-28 | $258.00K derived: sum of 3 quarters · filed 2022-02-28 | $4.65M 10-K · filed 2022-02-28 | $4.42M 10-K · filed 2020-03-06 | |||
| 2019-09-30 | $2.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$857.00K derived: sum of 2 quarters · filed 2020-11-06 | $3.54M 10-Q · filed 2020-11-06 | $3.54M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-30 | -$3.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $716.00K 10-Q · filed 2020-08-05 | $716.00K derived: sum of 3 quarters · filed 2021-03-01 | $716.00K derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-31 | $4.39M 10-Q · filed 2020-05-08 | $4.39M derived: sum of 2 quarters · filed 2021-03-01 | $4.39M derived: sum of 3 quarters · filed 2021-03-01 | $4.39M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $0.00 derived: sum of 2 quarters · filed 2021-03-01 | $0.00 derived: sum of 3 quarters · filed 2021-03-01 | $0.00 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $0.00 derived: sum of 2 quarters · filed 2019-11-08 | $0.00 10-Q · filed 2019-11-08 | |||||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $0.00 10-Q · filed 2019-08-08 | ||||||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |